

a.) Remarks

I. In the outstanding Office Action, the Examiner is requiring that Applicants elect one of the inventions of:

Group I (Claims 1-21, 29 and 30), drawn to a recombinant antibody;

Group II (Claims 22-25), drawn to DNA encoding the recombinant antibody and a method for producing the antibody; or

Group III (Claims 27-28), drawn to a method of treat IGF-associated disease, which comprises administering a therapeutically effective amount of the recombinant or the antibody fragment.

In response, Applicants hereby elect to prosecute the invention of Group I, namely claims 1-21, 29 and 30, drawn to a recombinant antibody.

II. Also, the Examiner is requesting that Applicants select a species for the antibody VH region among:

a) SEQ ID NOS:5, 6 and 7; and

b) SEQ ID NO:26.

In response, Applicants hereby select species a) SEQ ID NOS:5, 6 and 7.

III. Finally, the Examiner is requesting that Applicants select a species for the antibody VL region among:

c) SEQ ID NOS: 8, 9 and 10;

d) SEQ ID NO:27;

e) SEQ ID NO:28; and

f) SEQ ID NO:29.

In response, Applicants hereby select species c) SEQ ID NOS:8, 9 and 10.

However, Applicants wish to point out to the Examiner MPEP §821.04 which addresses the issue of processes "limited to making or using a nonobvious product" and stated that claims to the nonelected process should be rejoined when a product claim is found allowable and the withdrawn process contains all the limitations of an allowed product claim.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/
Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

FCHS_WS 1639378_1.DOC